FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases

Inclusion Criteria: * ECOG perfomance 0-1 * pathologically confirmed colorectal carcinoma, with RAS wild type * inital unresectable liver metastases discussed by MDT * prior no systemical therapy or exceed 6 months after the adjuvant chemotherapy of primary tumor surgery. * without extraheptic metastatic lesions, except for locally controlled lung metastases (RFA or SBRT) * adequate blood, liver and renal function * expected survival longer than 6 months Exclusion Criteria: * with bleeding risk * interestinal obstruction or disease * uncontrolled hypertension and severe heart disease * previous severe thrombotic events * central nervous system metastases * accompanied with other malignant tumor